Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Conivaptan: a selective vasopressin antagonist.

Nasir Z Sulemanjee1, Ernst R Schwarz

  • 1Division of Cardiology, Department of Internal Medicine, the University of Texas Medical Branch, Galveston, Texas, USA.

Drugs of Today (Barcelona, Spain : 1998)
|July 18, 2006
PubMed
Summary

Arginine vasopressin (AVP) is crucial for volume homeostasis and is elevated in conditions like heart failure. Blocking AVP receptors, as with conivaptan, is a promising therapeutic strategy for managing these diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hemodynamic Profiles During Pulmonary Artery Pressure Sensor Implantation: Risk Stratification in Chronic Heart Failure With Reduced Ejection Fraction.

Journal of cardiac failure·2025
Same author

Clinical Outcomes With Normothermic Pulsatile Organ Perfusion in Heart Transplantation: A Report From the OCS Heart Perfusion Registry.

Circulation·2025
Same author

A principal components analysis of factors associated with successful implementation of an LVAD decision support tool.

BMC medical informatics and decision making·2021
Same author

Benefits of Neurohormonal Therapy in Patients With Continuous-Flow Left Ventricular Assist Devices.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2019
Same author

The association between novel clinical factors and gastrointestinal bleeding among patients supported with continuous-flow left ventricular assist device therapy.

Journal of cardiac surgery·2019
Same author

Malignant cardiac phenotypic expression of Danon disease (LAMP2 cardiomyopathy).

International journal of cardiology·2017

Area of Science:

  • Endocrinology
  • Cardiology
  • Nephrology

Background:

  • Neurohormonal pathways critically regulate body fluid balance.
  • Arginine vasopressin (AVP) plays a central role in volume homeostasis.
  • Chronic AVP elevation is observed in pathological states, notably congestive heart failure (CHF).

Purpose of the Study:

  • To review the role of arginine vasopressin (AVP) in volume status regulation.
  • To discuss the detrimental effects of elevated AVP in disease progression, particularly in CHF.
  • To present conivaptan, a novel dual vasopressin receptor antagonist, as a therapeutic agent.

Main Methods:

  • Literature review of neurohormonal interactions in volume homeostasis.
  • Analysis of the role of AVP in cardiovascular and renal pathophysiology.

Related Experiment Videos

  • Examination of clinical research on vasopressin receptor antagonists.

    • Main Results:

    • Elevated serum AVP levels are implicated in the pathogenesis and progression of volume-related diseases.
    • AVP exerts deleterious receptor-mediated effects on vascular smooth muscle and cardiomyocytes.
    • Vasopressin receptor antagonists are emerging as key therapeutic targets in heart failure management.

    Conclusions:

    • AVP antagonism represents a significant therapeutic avenue for managing volume dysregulation.
    • Conivaptan, a dual V1a/V2 antagonist, shows potential in clinical research for heart failure.
    • Targeting vasopressin pathways offers a novel approach to treating complex cardiovascular and volume-related disorders.